A carregar...
Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary...
Na minha lista:
| Publicado no: | Front Immunol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879677/ https://ncbi.nlm.nih.gov/pubmed/33584689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.611549 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|